Iemura Tomoki, Kitano Toshiyuki, Ishii Akira, Hishizawa Masakatsu, Kondo Tadakazu, Yamashita Kouhei, Takaori-Kondo Akifumi
Department of Hematology, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, , 606-8507, Japan.
Clin J Gastroenterol. 2019 Oct;12(5):414-419. doi: 10.1007/s12328-019-00959-x. Epub 2019 Mar 5.
A 56-year-old man underwent cord blood transplantation for angioimmunoblastic T-cell lymphoma. He developed severe diarrhea and abdominal pain that persisted for more than 4 months. We suspected that he might have cord colitis syndrome (CCS), so metronidazole (MNZ) was administered. The patient's abdominal pain and diarrhea showed some improvement after the initiation of MNZ therapy, but they worsened on the cessation of MNZ, which prompted us to resume MNZ treatment. After the patient had taken MNZ (1500-2000 mg/day) for 78 days, he developed somnolence and dysarthria. We diagnosed him with metronidazole-induced encephalopathy (MIE) based on the characteristic magnetic resonance imaging findings and the clinical course. The patient's dysarthria and somnolence improved within a few days after the discontinuation of MNZ. CCS is a recently proposed clinical entity defined as a persistent diarrheal illness that is culture-negative, antibiotic-responsive, and not attributable to any known cause. Patients with CCS often have recurrent diarrhea after the discontinuation of MNZ and may require prolonged treatment for a median of 120 days. When treating CCS with MNZ, physicians should be alert for the development of MIE.
一名56岁男性因血管免疫母细胞性T细胞淋巴瘤接受了脐血移植。他出现了严重腹泻和腹痛,持续超过4个月。我们怀疑他可能患有脐结肠炎综合征(CCS),于是给予甲硝唑(MNZ)治疗。在开始MNZ治疗后,患者的腹痛和腹泻有所改善,但在停用MNZ后病情恶化,这促使我们重新开始MNZ治疗。在患者服用MNZ(1500 - 2000毫克/天)78天后,出现了嗜睡和构音障碍。基于特征性的磁共振成像表现和临床病程,我们诊断他为甲硝唑诱发的脑病(MIE)。在停用MNZ后的几天内,患者的构音障碍和嗜睡症状有所改善。CCS是最近提出的一种临床病症,定义为持续性腹泻疾病,培养结果为阴性,对抗生素有反应,且不归因于任何已知原因。CCS患者在停用MNZ后常出现复发性腹泻,可能需要中位时长为120天的长期治疗。在用MNZ治疗CCS时,医生应警惕MIE的发生。